Exploring the incidence of dysplasia or adenocarcinoma in early onset Barrett’s esophagus
Endoscopy · 01.12.2024 · 56 (12) · 906-912
DOI: 10.1055/a-2386-7843 ↗Kurz gefasst
Fachartikel in der Zeitschrift Endoscopy, erschienen am 01.12.2024. Verfasst von Irma C Noordzij und 5 weiteren Autor:innen. Beteiligte Einrichtung: Gastroenterology and Hepatology, Catharina Ziekenhuis, Eindhoven, Netherlands. Hauptthemen laut MEDLINE: Barrett Esophagus, Adenocarcinoma, Esophageal Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Catharina onderzoeksfonds.
Abstract (Originalsprache)
Background
Currently data on the risk of progression to and lifetime risk of cancer are not available for patients with young onset Barrett’s esophagus (BE). Our aim was to obtain epidemiologic data on the incidence of dysplasia or adenocarcinoma in young onset BE in the Netherlands by collecting data on all histologically confirmed cases over a prolonged period of 25 years between January 1, 1991 and December 31, 2015.
Methods
Data were obtained from the Dutch National Pathology Registry. Patients were included if there was a suspicion of BE visualized in the esophagus during the endoscopic examination in combination with a concordant histologic diagnosis of intestinal metaplasia.
Results
231 patients with early onset BE were identified (median age 26 years [range 0–29 years]), with 17 progressing to dysplasia (6 prevalent and 11 incident). For the patients with incident dysplasia, the median surveillance time between the diagnosis of early onset BE and diagnosis of dysplasia was 5 years (range 0–16 years). The incidence rate of dysplasia was 7.3 per 1000 person-years. There were three patients who developed adenocarcinoma (1 prevalent and 2 incident), who were diagnosed at ages 28, 35, and 36 years. The incidence rate of adenocarcinoma was 1.3 per 1000 person-years.
Conclusions
In this 25-year period, 231 patients were diagnosed with early onset BE in the Netherlands, with 17 patients progressing to dysplasia and three developing adenocarcinoma. This corresponded to incidence rates of 7.3 per 1000 person-years for dysplasia and 1.3 per 1000 person-years for adenocarcinoma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Gastroenterology and Hepatology, Catharina Ziekenhuis, Eindhoven, Netherlands.
- GROW School for Oncology and Reproduction, Maastricht University, Maastricht, Netherlands.
- Pathology, Eurofins PAMM BV Laboratorium voor Pathologie, Eindhoven, Netherlands.
- Gastroenterology and Hepatology, Maastricht University Medical Centre+, Maastricht, Netherlands.
- Onocology, Maastricht University GROW School for Oncology and Reproduction, Maastricht, Netherlands.
ORCID-Profile: Irma C Noordzij
Förderung
- Catharina onderzoeksfonds
Zitieren
APA
Noordzij, I. C., Huysentruyt, C. J., Curvers, W. L., van Lijnschoten, G., Masclee, A. A. M., & Schoon, E. J. (2024). Exploring the incidence of dysplasia or adenocarcinoma in early onset Barrett’s esophagus. Endoscopy, 56(12), 906-912. https://doi.org/10.1055/a-2386-7843
Vancouver
Noordzij IC, Huysentruyt CJ, Curvers WL, van Lijnschoten G, Masclee AAM, Schoon EJ. Exploring the incidence of dysplasia or adenocarcinoma in early onset Barrett’s esophagus. Endoscopy. 2024;56(12):906-912. doi:10.1055/a-2386-7843
BibTeX
@article{Noordzij2024,
author = {Noordzij, Irma C and Huysentruyt, Clément J and Curvers, Wouter L and van Lijnschoten, Gesina and Masclee, Ad A M and Schoon, Erik J},
title = {Exploring the incidence of dysplasia or adenocarcinoma in early onset Barrett’s esophagus},
journal = {Endoscopy},
year = {2024},
volume = {56},
number = {12},
pages = {906--912},
doi = {10.1055/a-2386-7843}
}
EUVIMED